Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 223

1.

Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.

Fendler WP, Philippe Tiega DB, Ilhan H, Paprottka PM, Heinemann V, Jakobs TF, Bartenstein P, Hacker M, Haug AR.

J Nucl Med. 2013 Aug;54(8):1202-8. doi: 10.2967/jnumed.112.116426. Epub 2013 May 31.

PMID:
23729697
[PubMed - indexed for MEDLINE]
Free Article
2.

18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.

Haug AR, Tiega Donfack BP, Trumm C, Zech CJ, Michl M, Laubender RP, Uebleis C, Bartenstein P, Heinemann V, Hacker M.

J Nucl Med. 2012 Mar;53(3):371-7. doi: 10.2967/jnumed.111.096230. Epub 2012 Feb 13.

PMID:
22331219
[PubMed - indexed for MEDLINE]
Free Article
3.

The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.

Zerizer I, Al-Nahhas A, Towey D, Tait P, Ariff B, Wasan H, Hatice G, Habib N, Barwick T.

Eur J Nucl Med Mol Imaging. 2012 Sep;39(9):1391-9. doi: 10.1007/s00259-012-2149-1. Epub 2012 May 30.

PMID:
22644713
[PubMed - indexed for MEDLINE]
4.

Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.

Piduru SM, Schuster DM, Barron BJ, Dhanasekaran R, Lawson DH, Kim HS.

J Vasc Interv Radiol. 2012 Jul;23(7):943-8. doi: 10.1016/j.jvir.2012.04.010. Epub 2012 May 19.

PMID:
22609292
[PubMed - indexed for MEDLINE]
5.

The prognostic value of quantitative parameters of 18F-FDG PET/CT in the evaluation of response to internal radiation therapy with yttrium-90 in patients with liver metastases of colorectal cancer.

Soydal C, Kucuk ON, Gecim EI, Bilgic S, Elhan AH.

Nucl Med Commun. 2013 May;34(5):501-6. doi: 10.1097/MNM.0b013e32835f9427.

PMID:
23478586
[PubMed - indexed for MEDLINE]
6.

Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?

Cook GJ, Yip C, Siddique M, Goh V, Chicklore S, Roy A, Marsden P, Ahmad S, Landau D.

J Nucl Med. 2013 Jan;54(1):19-26. doi: 10.2967/jnumed.112.107375. Epub 2012 Nov 30.

PMID:
23204495
[PubMed - indexed for MEDLINE]
Free Article
7.

Colorectal liver metastasis after 90Y radioembolization therapy: pilot study of change in MDCT attenuation as a surrogate marker for future FDG PET response.

Tochetto SM, Töre HG, Chalian H, Yaghmai V.

AJR Am J Roentgenol. 2012 May;198(5):1093-9. doi: 10.2214/AJR.11.6622.

PMID:
22528898
[PubMed - indexed for MEDLINE]
8.

Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.

Lastoria S, Piccirillo MC, Caracò C, Nasti G, Aloj L, Arrichiello C, de Lutio di Castelguidone E, Tatangelo F, Ottaiano A, Iaffaioli RV, Izzo F, Romano G, Giordano P, Signoriello S, Gallo C, Perrone F.

J Nucl Med. 2013 Dec;54(12):2062-9. doi: 10.2967/jnumed.113.119909. Epub 2013 Oct 17.

PMID:
24136935
[PubMed - indexed for MEDLINE]
9.

18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.

Huang WY, Kao CH, Huang WS, Chen CM, Chang LP, Lee MS, Chao HL, Chiu CH, Lo CH, Jen YM.

J Nucl Med. 2013 Oct;54(10):1710-6. doi: 10.2967/jnumed.112.119370. Epub 2013 Aug 22.

PMID:
23970365
[PubMed - indexed for MEDLINE]
10.

Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI.

Wong CY, Salem R, Raman S, Gates VL, Dworkin HJ.

Eur J Nucl Med Mol Imaging. 2002 Jun;29(6):815-20. Epub 2002 Mar 29.

PMID:
12029557
[PubMed - indexed for MEDLINE]
11.

Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging.

Wong CY, Qing F, Savin M, Campbell J, Gates VL, Sherpa KM, Lewandowski RJ, Nagle C, Salem R.

J Vasc Interv Radiol. 2005 Aug;16(8):1101-6.

PMID:
16105922
[PubMed - indexed for MEDLINE]
12.

90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT.

Bienert M, McCook B, Carr BI, Geller DA, Sheetz M, Tutor C, Amesur N, Avril N.

Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):778-87. Epub 2005 Mar 17.

PMID:
15772860
[PubMed - indexed for MEDLINE]
13.

Prognostic importance of 18F-FDG uptake pattern of hepatocellular cancer patients who received SIRT.

Kucuk ON, Soydal C, Araz M, Bilgic S, Ibis E.

Clin Nucl Med. 2013 Jul;38(7):e283-9. doi: 10.1097/RLU.0b013e3182867f17.

PMID:
23531737
[PubMed - indexed for MEDLINE]
14.

The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy.

Gulec SA, Suthar RR, Barot TC, Pennington K.

Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1289-95. doi: 10.1007/s00259-011-1758-4. Epub 2011 Apr 2.

PMID:
21461737
[PubMed - indexed for MEDLINE]
15.

Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography.

Szyszko T, Al-Nahhas A, Canelo R, Habib N, Jiao L, Wasan H, Pagou M, Tait P.

Nucl Med Commun. 2007 Jan;28(1):15-20.

PMID:
17159544
[PubMed - indexed for MEDLINE]
16.

Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET.

Wong CY, Salem R, Qing F, Wong KT, Barker D, Gates V, Lewandowski R, Hill EA, Dworkin HJ, Nagle C.

J Nucl Med. 2004 Nov;45(11):1892-7.

PMID:
15534060
[PubMed - indexed for MEDLINE]
Free Article
17.

Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer.

Heijmen L, de Geus-Oei LF, de Wilt JH, Visvikis D, Hatt M, Visser EP, Bussink J, Punt CJ, Oyen WJ, van Laarhoven HW.

Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1858-67. doi: 10.1007/s00259-012-2233-6. Epub 2012 Sep 4.

PMID:
22945372
[PubMed - indexed for MEDLINE]
18.

Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.

Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shih MC, Shimada N, Chen S, Salgia R, Appelbaum DE, Suzuki K, Chen CT, Pu Y.

Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):27-38. doi: 10.1007/s00259-011-1934-6. Epub 2011 Sep 23.

PMID:
21946983
[PubMed - indexed for MEDLINE]
19.

Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors.

Kucuk ON, Soydal C, Lacin S, Ozkan E, Bilgic S.

World J Surg Oncol. 2011 Aug 6;9:86. doi: 10.1186/1477-7819-9-86. Erratum in: World J Surg Oncol. 2011;9:120.

PMID:
21819613
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Does multidetector CT attenuation change in colon cancer liver metastases treated with 90Y help predict metabolic activity at FDG PET?

Tochetto SM, Rezai P, Rezvani M, Nikolaidis P, Berggruen S, Atassi B, Salem R, Yaghmai V.

Radiology. 2010 Apr;255(1):164-72. doi: 10.1148/radiol.09091028.

PMID:
20308454
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk